Common Contracts
324 similar Sales Agreement contracts by Schrodinger, Inc., Gorilla Technology Group Inc., Rubicon Technologies, Inc., others
Zentalis Pharmaceuticals, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • February 29th, 2024 • Zentalis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
SCHRÖDINGER, INC. Shares of Common Stock ($0.01 par value per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • February 29th, 2024 • Schrodinger, Inc. • Pharmaceutical preparations • New York
Reference is made to that certain Sales Agreement, entered into as of May 24, 2023 (the “Original Sales Agreement”) by and between Schrödinger, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC (the “Agent”). The Company and the Agent now intend to enter into this Amended and Restated Sales Agreement (this “Agreement”) to amend and restate the terms of the Original Sales Agreement in its entirety. Therefore, the Company confirms its agreement with the Agent as follows:
SCHRÖDINGER, INC. Shares of Common Stock ($0.01 par value per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • February 28th, 2024 • Schrodinger, Inc. • Pharmaceutical preparations • New York
Reference is made to that certain Sales Agreement, entered into as of May 24, 2023 (the “Original Sales Agreement”) by and between Schrödinger, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC (the “Agent”). The Company and the Agent now intend to enter into this Amended and Restated Sales Agreement (this “Agreement”) to amend and restate the terms of the Original Sales Agreement in its entirety. Therefore, the Company confirms its agreement with the Agent as follows:
SiTime Corporation Shares of Common Stock (par value $0.0001 per share) Sales AgreementSales Agreement • February 27th, 2024 • SITIME Corp • Semiconductors & related devices • New York
SiTime Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”), as follows:
Fulcrum Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 27th, 2024 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”; each individually an “Agent” and together, the “Agents”), as follows:
Desktop Metal, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 14th, 2024 • Desktop Metal, Inc. • Special industry machinery, nec • New York
Genelux Corporation Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • February 2nd, 2024 • GENELUX Corp • Pharmaceutical preparations • New York
Genelux Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Guggenheim Securities, LLC (the “Agent”), as follows:
Sales AgreementSales Agreement • January 26th, 2024 • Bridger Aerospace Group Holdings, Inc. • Services-business services, nec • New York
Bridger Aerospace Group Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”) and Virtu Americas LLC (“Virtu”; each an “Agent” and together, the “Agents”), as follows:
Invivyd, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • December 22nd, 2023 • Invivyd, Inc. • Biological products, (no disgnostic substances) • New York
Invivyd, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
MEIRAGTX HOLDINGS PLC Ordinary Shares (nominal value $0.00003881 per share) Sales AgreementSales Agreement • December 21st, 2023 • MeiraGTx Holdings PLC • Biological products, (no disgnostic substances) • New York
MeiraGTx Holdings plc, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with BofA Securities, Inc. (the “Agent”), as follows:
MODULAR MEDICAL, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • November 22nd, 2023 • Modular Medical, Inc. • Surgical & medical instruments & apparatus • New York
Modular Medical, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
RENEO PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • November 13th, 2023 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Archer Aviation Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • November 13th, 2023 • Archer Aviation Inc. • Aircraft • New York
Archer Aviation Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
IMMUNOVANT, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • November 9th, 2023 • Immunovant, Inc. • Biological products, (no disgnostic substances) • New York
Immunovant, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Sales AgreementSales Agreement • October 16th, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations • New York
Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
Innovative Solutions and Support, Inc. Shares of Common Stock (par value $0.001 per share) Sales AgreementSales Agreement • September 22nd, 2023 • Innovative Solutions & Support Inc • Services-computer programming services • New York
Innovative Solutions and Support, Inc., a Pennsylvania corporation (the “Company”), confirms its agreement (this “Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”), as follows:
Rubicon Technologies, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • September 11th, 2023 • Rubicon Technologies, Inc. • Services-prepackaged software • New York
Rubicon Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Rubicon Technologies, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • September 5th, 2023 • Rubicon Technologies, Inc. • Services-prepackaged software • New York
Rubicon Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
MOONLAKE IMMUNOTHERAPEUTICS Class A Ordinary Shares (par value $0.0001 per share) SALES AGREEMENTSales Agreement • August 31st, 2023 • MoonLake Immunotherapeutics • Pharmaceutical preparations • New York
MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Gorilla Technology Group Inc. Ordinary Shares (par value $0.0001 per share) Controlled Equity Offering Sales AgreementSales Agreement • August 17th, 2023 • Gorilla Technology Group Inc. • Services-prepackaged software • New York
Gorilla Technology Group Inc., a company organized under the laws of the Cayman Islands (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., (the “Agent”), as follows:
Gorilla Technology Group Inc. Ordinary Shares (par value $0.0001 per share) Controlled Equity Offering Sales AgreementSales Agreement • August 17th, 2023 • Gorilla Technology Group Inc. • Services-prepackaged software • New York
Gorilla Technology Group Inc., a company organized under the laws of the Cayman Islands (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., (the “Agent”), as follows:
RAPT Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 11th, 2023 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
On the date hereof, RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), has filed or will file with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 that contains a base prospectus as well as a sales agreement prospectus covering the offering, issuance and sale by the Company of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150,000,000. The parties agree to be legally bound by the terms of this Agreement effective immediately upon such registration statement being declared effective by the Commission.
Enovix Corporation Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 9th, 2023 • Enovix Corp • Miscellaneous electrical machinery, equipment & supplies • New York
Enovix Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. (collectively, the “Agents,” and individually, an “Agent”), as follows:
OCEAN POWER TECHNOLOGIES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 7th, 2023 • Ocean Power Technologies, Inc. • Electric services • New York
Ocean Power Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
NEXTCURE, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • August 4th, 2023 • NextCure, Inc. • Pharmaceutical preparations • New York
NextCure, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
REPLIMUNE GROUP, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • August 3rd, 2023 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • New York
Replimune Group, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Hepion Pharmaceuticals, Inc. Shares of Common Stock (par value $ 0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • July 21st, 2023 • Hepion Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
ASTRA SPACE, INC. Class A Common Stock ($0.0001 par value per share) Sales AgreementSales Agreement • July 10th, 2023 • Astra Space, Inc. • Transportation services • New York
Astra Space, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
Trevi Therapeutics, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • June 29th, 2023 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
HELIUS MEDICAL TECHNOLOGIES, INC. Class A Common Stock ($0.001 par value per share) Sales AgreementSales Agreement • June 23rd, 2023 • Helius Medical Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
Controlled Equity OfferingSM Sales AgreementSales Agreement • June 9th, 2023 • Contango ORE, Inc. • Gold and silver ores • New York
Contango ORE, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
SCHRÖDINGER, INC. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENTSales Agreement • May 24th, 2023 • Schrodinger, Inc. • Pharmaceutical preparations • New York
Schrödinger, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
ELOXX PHARMACEUTICALS, INC. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENTSales Agreement • May 24th, 2023 • Eloxx Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Eloxx Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows:
Caledonia Mining Corporation Plc Common Shares (no par value) Controlled Equity Offering Sales AgreementSales Agreement • May 18th, 2023 • Caledonia Mining Corp PLC • Gold and silver ores • New York
Caledonia Mining Corporation Plc, a Jersey, Channel Islands company (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
CULLINAN ONCOLOGY, INC. COMMON STOCK SALES AGREEMENTSales Agreement • May 11th, 2023 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Cullinan Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (the “Agent”), as follows:
